Nano-encapsulated HHC10 host defense peptide (HDP) reduces the growth of Escherichia coli via multimodal mechanisms
- 23 July 2018
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (sup3) , 156-165
Abstract
The eradication of several pathogenic drug resistant “Superbug” such as Escherichia coli became difficult especially in chronic infections using existing antibiotics due to the emergence of antibiotic resistance. Owing to their unique antibacterial properties, host defense peptides (HDP) have gained significant attention to combat colonization of bacteria. This study aims designing delivery systems for HHC10 peptide to target bacteria inside the cells might be a promising approach by protecting from degradation, controlling the release, enhancing the susceptibility of target microbes and improving bioavailability. Nano-formulated HHC10 was evaluated for its efficacy (CFU assay) and possible mechanism of action (membrane interaction and apoptosis) against E. coli. Dose-dependent inhibition of E. coli growth is observed for nano-encapsulated and bare HHC10 and encapsulated form remain non-toxic to macrophage mouse cells (RAW264.6) up to 20 μM. Mechanistic analyses using transmission electron microscopy and flow cytometry techniques revealed that bactericidal activity of HHC10-NP progresses via a multimodal mechanism of bacterial cell death by cell-membrane lysis on direct interaction with bacteria while through induction of the apoptotic death pathway inside the host cells. These results offer an insight on future strategies for the development and application of antimicrobial peptides as antibacterial alternatives. Controlled delivery of HHC10 peptide from PLGA-NP kills bacteria by two different mechanism: (i) direct killing: HHC10 disintegrate the cell membrane of bacteria by electrostatic interactions and (ii) indirect killing: induction of apoptosis in bacteria infect cells. Graphical AbstractKeywords
Funding Information
- Department of Science and Technology (YSS/2014/000053)
This publication has 35 references indexed in Scilit:
- The Synthetic Cathelicidin HHC-10 Inhibits Mycobacterium bovis BCG In Vitro and in C57BL/6 MiceMicrobial Drug Resistance, 2013
- The Future of Antibiotics and ResistanceNew England Journal of Medicine, 2013
- Antimicrobial Drug Resistance in Escherichia coli from Humans and Food Animals, United States, 1950–2002Emerging Infectious Diseases, 2012
- The myriad roles of cyclic AMP in microbial pathogens: from signal to swordNature Reviews Microbiology, 2011
- Membrane-active host defense peptides – Challenges and perspectives for the development of novel anticancer drugsChemistry and Physics of Lipids, 2011
- Antimicrobial peptides: key components of the innate immune systemCritical Reviews in Biotechnology, 2011
- Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant SuperbugsACS Chemical Biology, 2008
- Drug delivery approaches to overcome bacterial resistance to β-lactam antibioticsExpert Opinion on Drug Delivery, 2008
- Antimicrobial and host-defense peptides as new anti-infective therapeutic strategiesNature Biotechnology, 2006
- Antimicrobial peptides: premises and promisesInternational Journal of Antimicrobial Agents, 2004